How to Get Tresiba in California: Telehealth, Prescriptions, and Pharmacy Access

What Is Tresiba and Why Do Patients Seek It Specifically

Insulin degludec (Tresiba) is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, meaningfully longer than insulin glargine U-100 or detemir. [1] The FDA approved Tresiba in September 2015 for adults and subsequently for pediatric patients aged 1 year and older with type 1 or type 2 diabetes. [2]

The DEVOTE cardiovascular outcomes trial (N=7,637) compared insulin degludec to insulin glargine U-100 in high-risk patients with type 2 diabetes over a median follow-up of 2.0 years. Degludec met non-inferiority for major adverse cardiovascular events (MACE) and produced a 40% relative risk reduction in severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001 for superiority). [3] That hypoglycemia advantage drives demand for Tresiba from patients who experienced nocturnal lows on glargine.

The ADA 2024 Standards of Care state: "For patients with recurrent nocturnal or severe hypoglycemia, switching to an ultra-long-acting basal insulin such as insulin degludec or insulin glargine U-300 should be considered." [4] That guideline language gives California clinicians a direct rationale for prescribing Tresiba when a patient has documented hypoglycemia on a prior basal insulin.

Patients in California also search for Tresiba because flexible dosing timing, something glargine U-100 manufacturers recommend keeping strictly consistent, may fit shift-work or variable-schedule lifestyles. A crossover pharmacokinetic study (N=68) confirmed that deliberate dosing intervals ranging from 8 to 40 hours with degludec did not materially alter steady-state glucose-lowering effect compared to fixed 24-hour dosing. [5]

California Legal Framework for Prescribing Tresiba

California permits telehealth prescribing of controlled and non-controlled prescription medications provided a valid prescriber-patient relationship is established. Tresiba is not a controlled substance. California Business and Professions Code Section 2290.5 defines telehealth as "the mode of delivering health care services and public health" via technology and explicitly states that a prescriber-patient relationship may be established via telehealth without a prior in-person visit, provided the standard of care is met. [6]

Three practitioner categories may write a valid Tresiba prescription in California:

Physicians and osteopaths (MD, DO). All hold full independent prescriptive authority under California Business and Professions Code 2052. No additional certification is needed to prescribe insulin.

Nurse practitioners (NP). Under California AB 890, signed into law in 2020 and phased in by January 2023, NPs practicing in certain settings may prescribe independently without a physician's supervision or a standardized procedure agreement. [7] An NP prescribing Tresiba via telehealth for a patient with a confirmed diabetes diagnosis meets the scope requirement in most outpatient settings.

Physician assistants (PA). California PAs operate under a physician agreement. They may prescribe Schedule II through V controlled substances and all non-controlled drugs within their agreement scope, which routinely includes insulin management.

The California Medical Board has not issued any insulin-specific prescribing restrictions beyond the general standard-of-care requirement. Prescribers must document: confirmed diagnosis (type 1 or type 2 diabetes), current glycemic status (HbA1c, fasting glucose), prior basal insulin use or clinical rationale for starting degludec, and patient education on injection technique and hypoglycemia recognition. [8]

How to Get a Tresiba Prescription in California Step by Step

Getting Tresiba in California follows a four-stage process that typically spans 3 to 10 business days from initial consult to first injection.

Stage 1: Choose a prescriber pathway. Patients with an established endocrinologist or primary care physician may request Tresiba at their next visit or via a patient portal message citing documented hypoglycemia or control issues on a current basal insulin. Patients without an established provider, or those preferring speed, may use a California-licensed telehealth platform. Several national telehealth services hold California medical corporation registrations and can pair patients with in-state prescribers for an asynchronous or synchronous visit.

Stage 2: Complete required labs. No California law mandates specific pre-prescription labs for insulin, but the ADA 2024 Standards of Care recommend HbA1c measurement at least twice yearly in patients meeting treatment goals and quarterly when therapy is changing. [4] A prescriber initiating degludec will typically require a recent HbA1c (within 90 days), a basic metabolic panel to screen for renal impairment affecting dose adjustment, and documentation of current diabetes medications. [9]

Stage 3: Obtain and fill the prescription. The prescriber sends an electronic prescription to the patient's pharmacy of choice. California pharmacies may fill Tresiba from any state-licensed prescriber. Mail-order pharmacies licensed in California, including those operating as specialty pharmacies, may ship Tresiba directly to California addresses. Tresiba is available as a 100 units/mL FlexTouch pen (3 mL, 5-pen carton) and a 200 units/mL FlexTouch pen. [2]

Stage 4: Insurance or out-of-pocket processing. Commercial insurers in California often require prior authorization (PA) before covering Tresiba. Medi-Cal also covers Tresiba with PA for both type 1 and type 2 diabetes. Processing timelines for PA decisions average 3 to 5 business days for standard reviews under California Health and Safety Code 1367.01, which requires health plans to issue urgent PA decisions within 72 hours and standard decisions within 5 business days. [10]

Telehealth Prescribers for Tresiba in California

Telehealth has become the fastest route to a new Tresiba prescription for many California patients, particularly those in rural counties where endocrinologists are sparse. The 2023 California Health Interview Survey found that 36% of California adults with diabetes reported using a telehealth visit for diabetes management in the prior 12 months, a figure that rose from 12% in 2019. [11]

California telehealth prescribers evaluating a patient for insulin degludec will typically conduct a synchronous video visit of 20 to 30 minutes or request completion of an intake questionnaire reviewed asynchronously. The prescriber reviews HbA1c history, current insulin doses, hypoglycemia frequency, and any contraindications. There are no absolute contraindications to degludec other than hypersensitivity to insulin degludec or any excipients listed in the FDA label. [2]

A meta-analysis of telemedicine-delivered diabetes care (12 RCTs, N=1,490) published in JAMA Internal Medicine found that telemedicine interventions reduced HbA1c by a mean of 0.57% (95% CI 0.32 to 0.82) compared with usual care over 3 to 12 months. [12] That evidence base supports telehealth as a legitimate prescribing pathway, not a shortcut around clinical rigor.

After the telehealth visit, most platforms transmit the prescription electronically to the patient's preferred California-licensed pharmacy within 24 hours. Some platforms partner with mail-order pharmacies that handle PA submission, copay card enrollment, and cold-chain shipping for insulin products in a single workflow.

Prior Authorization for Tresiba in California: What Documentation Is Required

Most California commercial health plans and Medi-Cal Managed Care plans classify Tresiba as a non-preferred brand or specialty item requiring prior authorization before coverage is granted. Knowing exactly what the PA packet must contain saves 3 to 7 days of back-and-forth.

Standard California PA documentation requirements for insulin degludec typically include:

1. Confirmed diabetes diagnosis with ICD-10 code (E10.x for type 1, E11.x for type 2).
2. Current HbA1c value and date of measurement.
3. Documentation of at least one trial of a preferred formulary basal insulin (most plans list glargine biosimilars as step-therapy requirements). A 30-day trial is usually sufficient.
4. Record of inadequate glycemic control or hypoglycemia on the prior agent, with dates and severity.
5. Prescriber attestation that degludec is medically necessary.

California Health and Safety Code 1367.01 requires health plans to notify enrollees and prescribers of PA decisions within the statutory timeframes noted above. [10] If the initial PA is denied, California law grants the right to an expedited appeal within 30 days of the denial notice, and the plan must issue an expedited appeal decision within 72 hours of receipt. [13]

The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy states: "Insulin degludec and glargine U-300 are associated with lower rates of hypoglycemia compared with glargine U-100 and are preferred in patients with a history of severe or nocturnal hypoglycemia." [14] Including that guideline citation in a PA letter increases approval rates because it gives the reviewing medical director a named authoritative source rather than only the prescriber's clinical opinion.

California 503A Pharmacies and Insulin Degludec

503A pharmacies in California are traditional compounding pharmacies licensed by the California State Board of Pharmacy. They may compound insulin preparations on a patient-specific, prescription basis. The California Board of Pharmacy follows federal USP <797> sterile compounding standards for injectable preparations, including insulin. [15]

Commercially manufactured Tresiba (Novo Nordisk) is not compounded, but 503A pharmacies may prepare custom insulin degludec concentrations or dilutions if a prescriber documents a specific clinical need (for example, a pediatric patient requiring sub-unit dosing precision that commercial pen concentrations cannot deliver). The FDA does not place insulin degludec on the list of drugs that may not be compounded. [16]

Patients should confirm that any 503A pharmacy filling an insulin degludec preparation holds a current California Board of Pharmacy license. The board's license verification tool is publicly accessible at pharmacy.ca.gov. Compounded insulin products require proper cold-chain handling: refrigeration at 36 to 46 degrees Fahrenheit before opening, and no use beyond the beyond-use date specified by the pharmacy per USP <797> standards. [15]

Commercial Tresiba FlexTouch pens may be kept at room temperature (below 86 degrees Fahrenheit) for up to 56 days after first use, per the FDA-approved prescribing information. [2] Patients switching from a 503A-compounded insulin to commercial Tresiba should note this difference in storage requirements.

Transferring a Tresiba Prescription to California

Patients relocating to California who currently have an active Tresiba prescription from another state may transfer that prescription to a California-licensed pharmacy under the following conditions:

California Business and Professions Code 4064 permits transfer of a valid outpatient prescription between pharmacies. A prescription for a non-controlled drug like insulin degludec may be transferred once between pharmacies unless the original prescribing state or pharmacy has placed restrictions. [17]

The receiving California pharmacy will verify the prescription with the originating pharmacy or, for electronic prescriptions, via the electronic prescribing network. The prescription remains valid for one year from the date written for non-controlled medications under California law.

If the original prescriber is not licensed in California, the prescription remains valid for filling at a California pharmacy as long as it was issued by a practitioner licensed in the jurisdiction of origin. California pharmacists may fill out-of-state prescriptions for non-controlled drugs at their professional discretion. [17] Patients who need ongoing refills should establish care with a California-licensed prescriber, since out-of-state prescribers cannot issue new prescriptions for California patients without a California license or a qualifying interstate telehealth arrangement.

Tresiba Pricing and Savings Programs in California

The list price of Tresiba in the United States is approximately $320 to $380 per 5-pen FlexTouch carton (100 units/mL) without insurance. California patients have several pathways to reduce this cost.

Novo Nordisk Patient Assistance Program. Novo Nordisk offers the Novo Nordisk Patient Assistance Program (NovoCare) for uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level. Enrolled patients may receive Tresiba at no cost. [18]

Copay card. The Novo Nordisk My$99Insulin program caps cost for commercially insured patients at $99 per 90-day supply. As of 2024, this program applies to Tresiba FlexTouch. [18]

Medi-Cal. Medi-Cal covers Tresiba for both type 1 and type 2 diabetes with prior authorization. After PA approval, enrollees pay no more than the Medi-Cal co-payment, which is $0 for most Medi-Cal beneficiaries as of 2023 following the elimination of most Medi-Cal cost-sharing.

Covered California marketplace plans. Under the Inflation Reduction Act provisions adopted into California exchange plans, insulin cost-sharing is capped at $35 per month per covered insulin product beginning January 2023. [19] Patients on a Covered California plan who have completed the PA process for Tresiba pay no more than $35 per monthly supply regardless of plan tier.

GoodRx and discount cards. GoodRx and similar discount services list Tresiba at $180 to $250 per carton at major California chain pharmacies as of mid-2025. These prices apply only without using insurance and cannot be combined with Medi-Cal or Medicare.

Dosing Tresiba Correctly After You Receive Your Prescription

Starting dose for insulin-naive patients with type 2 diabetes is typically 10 units subcutaneously once daily, as stated in the FDA prescribing information. [2] For patients transitioning from another basal insulin (unit-for-unit conversion from glargine or detemir is generally appropriate), the starting degludec dose equals the prior basal total daily dose.

The FDA label recommends titrating Tresiba by 2 units every 3 to 4 days until fasting self-monitored blood glucose reaches the individual target, typically 80 to 130 mg/dL per ADA 2024 goals. [2][4] Titration should not occur more frequently than every 3 days because degludec takes approximately 3 to 4 days to reach steady state given its prolonged half-life. [1]

A 26-week randomized treat-to-target trial (BEGIN Once Long, N=1,030) confirmed that once-daily degludec achieved comparable HbA1c reduction to once-daily glargine U-100 (estimated treatment difference 0.09%, 95% CI -0.04 to 0.22) with significantly fewer confirmed nocturnal hypoglycemic episodes (25% lower rate, P<0.001). [20]

Patients with type 1 diabetes require concurrent rapid-acting insulin coverage for meals; degludec alone does not cover postprandial excursions. The FDA label specifies that degludec must be used with rapid-acting insulin in type 1 diabetes. [2]

Monitoring After Starting Tresiba in California

After initiating degludec, the ADA recommends HbA1c assessment at 3 months if glycemic goals are not met or therapy has changed, and every 6 months once stable. [4] California telehealth prescribers and in-person physicians typically schedule a follow-up visit or asynchronous chart review at 4 to 6 weeks after initiation to review fasting glucose logs and adjust dose.

Key monitoring parameters include fasting capillary blood glucose (daily, self-monitored), symptoms of hypoglycemia, injection site reactions, and renal function in patients with chronic kidney disease (CKD). No dose adjustment is specified in the FDA label for renal impairment, but more frequent glucose monitoring is recommended because renal clearance of insulin may be altered in CKD stages 3 through 5. [2][9]

Patients using continuous glucose monitoring (CGM) devices should set low glucose alert thresholds at 70 mg/dL per ADA 2024 guidance and review time-in-range data (target: more than 70% of readings between 70 and 180 mg/dL) at each clinical contact. [4] CGM data can be shared remotely with California telehealth providers via most platform integrations, supporting asynchronous dose titration between scheduled visits.